Dublin, December 31, 2021 (GLOBE NEWSWIRE) – The “Chinese Leuprorelin Market Investigation Report 2021-2025” the report was added to ResearchAndMarkets.com offer.
According to the market research, the sales value of Leuprorelin in the Chinese market increased rapidly year on year from 2016 to 2019.
Due to the impact of the COVID-19 epidemic on all diagnostic and treatment departments of the hospital, the growth rate of sales value increased from 21.01% in 2019 to 11 , 11% in 2020. The sales value of Leuprorelin in the Chinese market reached CNY 1,108 million in 2020 and the CAGR was 15.1% from 2016 to 2020.
Leuprolide is a synthetic gonadotropin drug used to treat hormone-sensitive cancers such as prostate cancer and breast cancer. It can also be used to treat precocious puberty and prevent premature ovulation during in vitro fertilization. Leuprolide was patented in 1973 and approved for medical use in the United States in 1985.
In 1992, she obtained the license to import medicines from China. By the first half of 2021, Chinese leuprolide market manufacturers are Takeda Pharmaceutical Co., Ltd., Shanghai Livzon Pharmaceutical Co., Ltd. and Beijing Biote Pharmaceutical Co., Ltd.
The analyst expects that with the mitigation of the COVID-19 epidemic, sales of Leuprorelin will experience restorative growth from 2021 to 2025. On August 10, 2020, Shanghai-Takeda China announced that its shape 3-month dosage (specification: 11.25 mg) of Innate has been officially approved by the National Medicines Administration of China for the treatment of central precocious puberty (PCP).
This is the third indication approved in China for the 3-month dosage form of Innate. As the number of indications increases, the volume of sales of leuprolide is expected to increase, and sales may increase.
- The impact of COVID-19 on the Chinese leuprorelin market
- 2016-2020 Chinese Leuprorelin Sales Value
- Competitive Landscape of the Chinese Leuprorelin Market
- Price of leuprorelin in China
- China Leuprorelin Price by Regions and Manufacturers
- Analysis of factors affecting the development of the China Leuprorelin Market
- China Leuprorelin Market Outlook from 2021 to 2025
Main topics covered:
1 Relevant concepts of leuprorelin
1.1 Indications for leuprorelin
1.2 Development of Leuprorelin in China
1.3 Government approval of leuprorelin in China
1.4 The impact of COVID-19 on sales of leuprorelin in China
2 Sales of Leuprorelin in China, 2016-2020
2.1 Leuprorelin sales value
2.1.1 Overall value of sales
2.1.2 Sales value by region
2.2 Leuprorelin Sales Volume
2.2.1 Global sales volume
2.2.2 Sales Volume by Region
2.3 China Leuprorelin Sales by Dosage Form, 2016-2020
2.3.1 Beads for injection
2.3.2 Analysis of another dosage form
3 Major Manufacturers Analysis of China Leuprorelin in 2020
3.1 Major Manufacturers of Leuprorelin Market Share Analysis
3.1.1 Market Share by Sales Value Survey
3.1.2 Market Share by Sales Volume Survey
3.2 Takeda Pharmaceutical Co., Ltd.
3.2.1 Company profile
3.2.2 Sales of ENANTONE (Leuprorelin by Takeda Pharmaceutical Co., Ltd.) in China
3.3 Shanghai Livzon Pharmaceutical Co., Ltd.
3.3.1 Company profile
3.3.2 Sales of Beiyi (Leuprorelin de Shanghai Livzon Pharmaceutical Co., Ltd.) in China
3.4 Beijing Biote Pharmaceutical Co., Ltd.
3.4.1 Company profile
3.4.2 Sales of Boennuokang (Leuprorelin de Beijing Biote Pharmaceutical Co., Ltd.) in China
4 Leuprorelin Price for Different Manufacturers in China, 2020-2021
4.1 Takeda Pharmaceutical Co., Ltd. (ENANTONE)
4.2 Shanghai Livzon Pharmaceutical Co., Ltd. (Beiyi)
4.3 Beijing Biote Pharmaceutical Co., Ltd. (Boennuokang)
5 China Leuprorelin Market Outlook, 2021-2025
5.1 Factors influencing the development of the Chinese Leuprorelin Market
5.1.1 The impact of COVID-19 on the Chinese leuprorelin market
5.1.2 Market Drivers and Opportunities
5.1.3 Market threats and challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast
- Takeda Pharmaceutical Co., Ltd.
- Shanghai Livzon Pharmaceutical Co., Ltd.
- Beijing Biote Pharmaceutical Co., Ltd.
For more information on this report, visit https://www.researchandmarkets.com/r/6qrv6h